Your browser doesn't support javascript.
loading
Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002-2018).
Tan, Jian Liang; Jin, Chengyue; Lee, Justin Z; Gaughan, John; Iwai, Sei; Russo, Andrea M.
Afiliação
  • Tan JL; Division of Cardiovascular Disease, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
  • Jin C; Department of Medicine, Westchester Medical Center, Valhalla, New York, USA.
  • Lee JZ; Department of Cardiology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Gaughan J; Cooper Research Institute, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
  • Iwai S; Department of Cardiology, Westchester Medical Center, Valhalla, New York, USA.
  • Russo AM; Division of Cardiovascular Disease, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
J Cardiovasc Electrophysiol ; 33(12): 2585-2598, 2022 12.
Article em En | MEDLINE | ID: mdl-36335632
INTRODUCTION: Data on utilization, major complications, and in-hospital mortality of catheter ablation (CA) for sarcoidosis-related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis-related VT, and incidence and predictors of complications associated with the CA procedure. METHODS: We queried the 2002-2018 National Inpatient Sample database to identify patients aged ≥18 years with sarcoidosis admitted with VT. A 1:3 propensity score-matched (PSM) analysis was used to compare patient outcomes between CA and medically managed groups. Multivariable regression was performed to determine independent predictors of in-hospital mortality and procedural complications associated with the CA procedure. RESULTS: Of 3220 sarcoidosis patients with VT, 132 (4.1%) underwent CA. Patients who underwent CA were younger, male predominant, more likely Caucasian, had differences in baseline comorbidities including more likely to have heart failure, less likely to have prior myocardial infarction, COPD, or severe renal disease, had a higher mean household income, and more likely admitted to a larger/urban teaching hospital. After PSM, we examined 106 CA cases and 318 medically managed cases. There was a trend toward a lower in-hospital mortality rate in the CA group when compared to the medically managed group (1.9% vs. 6.6%, p = 0.08). The most common complications were pericardial drainage (5.3%), postoperative hemorrhage (3.8%), accidental puncture periprocedure (3.0%), and cardiac tamponade (2.3%). Independent predictors of in-hospital mortality and procedural complications among the CA group included congestive heart failure (odds ratio [OR], 13.2; 95% confidence interval [CI], 1.7-104.2) and mild to moderate renal disease (OR, 3.9; 95% CI, 1.1-13.3). CONCLUSIONS: Compared to patients with sarcoidosis-related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure-related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoidose / Taquicardia Ventricular / Ablação por Cateter Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoidose / Taquicardia Ventricular / Ablação por Cateter Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article